Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × balstilimab × 30 days × Clear all

Phase

Phase 3 2 Phase 1 2 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Resectable MMR-deficient Solid Tumors 1

Interventions

Magnetic Resonance Spectroscopy 13 Cisplatin 13 Specimen Handling 11 Doxorubicin 10 Carboplatin 10 pembrolizumab 7 Radiotherapy 7 Nivolumab 7 Gemcitabine 7 Radiation 6 Platinum 6 Paclitaxel 6 Bevacizumab 6 1,2-diaminocyclohexaneplatinum II citrate 6 atezolizumab 5 Ipilimumab 5 Cyclophosphamide 5 Biopsy 5 venetoclax 4 Vincristine 4 Rituximab 4 Pemetrexed 4 Immunoglobulin G 4 Docetaxel 4 Disulfides 4 Taxes 3 Radiotherapy, Intensity-Modulated 3 Prednisone 3 Oxaliplatin 3 Methotrexate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06279130 2026-03-05

NEOASIS

The Netherlands Cancer Institute

Phase 2/3 Recruiting

Other solid neoplasm

Resectable MMR-deficient Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡